Monday, June 20, 2011

Business Rx: Tau Therapeutics

Tau Therapeutics article in The Washington Post today.

Andrew Krouse was working at the University of Virginia when he learned about a revolutionary technology his neighbor, a professor of medicine, was developing that could be the key to cancer treatment. Not long after, Krouse joined the team and is now president and chief executive of Tau Therapeutics, a life-sciences company based in Charlottesville that is developing a nontoxic pill it believes can stop cancer and block the side effects of chemotherapy and radiation.

The pitch


“Our clinical priority for the technology we licensed from U-Va. is a program we call Interlaced Therapy. It promises to significantly enhance the efficacy of chemotherapy in a number of serious cancers. It works by halting the dividing cancer cells so that standard chemotherapies are more powerful. We have patented and received orphan drug designation on a drug that was on the market for hypertension and are repositioning this drug for the treatment of cancer. By taking our nontoxic drug in a sequential combination with a standard chemotherapy, we hope to minimize chemotherapy’s terrible side effects and greatly enhance the effectiveness of these therapies. There’s also the potential to overcome drug resistance.

Click here to read the complete article in The Washington Post.

No comments: